Volastra
Nazario Bosco is an accomplished scientist with extensive experience in biology, currently serving as the Associate Director of Biology at Volastra Therapeutics since April 2021, where previously held the title of Senior Scientist. Prior to this role, Nazario worked at NYU Langone Health from 2018 to April 2021 as a Senior Research Scientist, focusing on chromosome-specific patterns in cancer and developing the patented system 'KaryoCreate' for inducing chromosome-specific aneuploidy in human cells. Earlier experience includes a research associate position at The Rockefeller University from 2011 to 2018, where studies centered on telomere crisis and genome instability, as well as a postdoctoral researcher role investigating the human telomeric protein TRF1. Nazario obtained a PhD in Genetics and Molecular Biology from Sapienza Università di Roma in 2011, along with a Master's degree in 2008 and a Bachelor's degree in 2006 in the same field.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.